Delivery Order SPE2DB22D3102-SPE2DB25FL2QJ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $11,568.32 to AmerisourceBergen Drug Corp for Synvisc-One syringes (6mL) on August 4, 2025, with an ultimate completion date of August 5, 2025. This firm fixed-price delivery order represents a non-competitive set-aside and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Synvisc-One is a hyaluronic acid-based injectable used for knee osteoarthritis treatment, indicating this procurement...
- The Defense Logistics Agency awarded a $2,370.86 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Synvisc-One Syringe 6ML, a hyaluronic acid injection used for knee osteoarthritis treatment. This non-set-aside, competitively awarded contract is scheduled for completion by July 21, 2025, with performance occurring at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 21, 2025, for the supply of Synvisc-One syringes (6mL) with a ceiling value of $3,885.12 under a firm fixed-price contract type. The contract is non-set-aside and competitively awarded, with an ultimate completion date of July 22, 2025. Performance will be executed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $19,398.41 on July 29, 2025, for the supply of Synvisc-One syringes (6mL, 1 unit). This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 25, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract requires no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a $1,729.05 delivery order to AmerisourceBergen Drug Corp for Synvisc-One Syringe 6ML, a pharmaceutical product used in joint pain management. This firm fixed price contract, issued on July 29, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery order specifies a place of performance in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,012.91 on August 8, 2025, for the supply of Synvisc-One Syringe 6ML, a pharmaceutical product for joint pain management. This is a firm fixed price contract with no set-aside designation, competitively awarded under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The delivery order is scheduled for completion by August 11, 2025, with performance based in...
- The Defense Logistics Agency awarded a $2,703.12 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 4561970712 SYNVISC-ONE SYRINGE 6ML. The single syringe package of Synvisc-One, an injectable treatment for osteoarthritis-related pain in the knee, will be delivered to a facility in Conshohocken, Pennsylvania by August 30, 2023 to support the Agency's medical supply needs. As a top pharmaceutical distributor, Amerisourcebergen will likely fulfill the order from existing...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the for-profit organization Amerisourcebergen Corporation, for the supply of Synvisc-One syringe 6 ml. The contract has a potential value of $1,605.08 and a completion date of March 1, 2024. This delivery order is issued under an indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp with DLA with a potential value of...
- This contract award, with a ceiling value of $4,722.12, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp. The contract provides for the delivery of Synvisc-One syringes, a pharmaceutical product used for the treatment of knee osteoarthritis. This is a Firm Fixed Price delivery order contract with no set-aside designation. Amerisourcebergen, as a major pharmaceutical distributor, leverages its extensive supply chain...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,051.94 firm fixed-price delivery order is for the supply of SYNVISC-ONE SYRINGE 6ML, a medical product used in the treatment of osteoarthritis. The contract has an ultimate completion date of November 25, 2024 and was awarded on November 22, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite...
- SPE2DB22D3102Indefinite Delivery Contract
- SPE2DB22D3102-SPE2DB25FL2QJDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Synvisc-One syringes (6mL) with a ceiling value of $1,311.78. This is a firm fixed-price delivery order with an ultimate completion date of August 18, 2025, and represents a non-set-aside competitive award. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending through December 2026. Synvisc-One is a viscosupplement medication used for knee osteoarthritis treatment, reflecting the Defense Logistics Agency's broader medical supply procurement to support military healthcare systems. AmerisourceBergen Drug Corp, as a major pharmaceutical distributor and critical federal vendor, supplies an extensive portfolio of medications, vaccines, and medical devices to military and veteran healthcare programs. The non-set-aside competitive award demonstrates the company's continued capability to meet federal procurement requirements through open competition, maintaining its role as a primary pharmaceutical provider for the Department of Defense medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 8/15/25 |